---
title: "Lilly expects Q2 acquired IPR&D charge of about $2.8 billion pretax, $3.02/sh hit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292112302.md"
description: "Eli Lilly anticipates a $2.8 billion pre-tax acquired IPR&D charge in Q2 2026, driven by costs from collaborations and asset acquisitions. This charge is expected to reduce both GAAP and non-GAAP earnings per share by approximately $3.02."
datetime: "2026-07-08T20:33:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292112302.md)
  - [en](https://longbridge.com/en/news/292112302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292112302.md)
---

# Lilly expects Q2 acquired IPR&D charge of about $2.8 billion pretax, $3.02/sh hit

-   Eli Lilly expects Q2 2026 acquired IPR&D charges of about USD 2.8 billion on a pre-tax basis. \* The charge is forecast to cut both GAAP and non-GAAP EPS by about USD 3.02. \* The estimate reflects anticipated costs tied to collaborations, licensing deals, or other asset acquisitions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)

## Related News & Research

- [HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%](https://longbridge.com/en/news/293701781.md)
- [Lilly Targets Early 2027 Filing for Next Obesity Drug](https://longbridge.com/en/news/293649982.md)
- [Eli Lilly's Retatrutide Meets Primary Endpoint In Phase 3 TRIUMPH-2 And TRIUMPH-3 Trials](https://longbridge.com/en/news/293605576.md)
- [Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application](https://longbridge.com/en/news/293600518.md)
- [Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials](https://longbridge.com/en/news/293607076.md)